Interventions for acute depression study characteristics. Abbreviations Australia bipolar I disorder. Great Britain

Transcription

1 APPENDIX 16: INTERVENTIONS FOR ACUTE DEPRESSION STUDY CHARACTERISTICS 1.1 Pharmacological interventions Nutritional interventions Physical interventions... 7 Abbreviations BPI CHN Dur ESP FRA Freq GBR GER IND JPN KOR N N/A N Post NR N Rand NLD POL ROU RUS RSA TAU TMS TWN UKR USA XR Australia bipolar I disorder China duration Spain France frequency Great Britain Germany India Japan Korea number of participants not applicable number of participants at post-treatment not reported number of participants randomised Netherlands Poland Romania Russia Republic of South Africa treatment as usual transcranial magnetic stimulation Taiwan Ukraine United States of America extended release 1

2 1.1 PHARMACOLOGICAL INTERVENTIONS Aripiprazole compared with placebo BRISTOLMYERSSQUIB2006 USA None BRISTOLMYERSSQUIB2007 USA None QUANTE2010 GER Bupropion, sertraline and venlafaxine POST2006 NLD, GER Imipramine compared with moclobemide SILVERSTONE2001 USA Lamotrigine compared with placebo Citalopram with lithium or valproate Mood stabiliser and/or an antipsychotic Mood stabilisers, single benzodiazepine hypnotic Aripiprazole 10 mg Placebo N/A Aripiprazole 10 mg Placebo N/A Aripiprazole 15 mg Placebo N/A Bupropion 280 mg Setraline 190 mg Venlafaxine 195 mg Imipramine 150 mg Moclobemide 600 mg 7 8 CALABRESE1999 CALABRESE2005 GBR, FRA, GBR, FRA, None Benzodiazepines (limited use) Lamotrigine 50 mg Lamotrigine 200 mg Placebo Placebo NR Quetiapine 300 mg NR Quetiapine 600 mg NR Placebo N/A 7 8 CALABRESE2008a USA NR NR Lamotrigine 200 mg

3 Placebo N/A 7 10 CALABRESE2008b USA NR CALABRESE2008c USA NR CALABRESE2008d USA NR VANDERLOOS2009 Lamotrigine, gabapentin and placebo NLD, ESP Lithium FRYE2000 USA NR Lurasidone compared with placebo Levothyroxine, triiodothyronine and clonazepam in phase I Lamotrigine 200 mg Placebo N/A Lamotrigine 200 mg Placebo N/A Lamotrigine 200 mg Placebo N/A Lamotrigine 200 mg Placebo N/A 7 8 NR NR Lamotrigine 300 mg 7 6 NR NR Gabapentin 3,980 mg 7 6 NR NR Placebo N/A 7 6 SUNOVION2012a GER, IND, POL, ROU, RUS, RSA, UKR, USA Lithium or valproate Lurasidone 65 mg Placebo N/A 7 6 SUNOVION2012b GBR, FRA, Lithium or valproate Lurasidone 32 mg Lurasidone 80 mg 7 6 3

4 Placebo N/A 7 6 Olanzapine compared with placebo TOHEN2012 JPN, CHN, TWN, KOR, USA Olanzapine and fluoxetine combination compared with lamotrigine NR BROWN2006 USA Anticholinergics, benzodiazepines or other hypnotics Olanzapine 10 mg Placebo N/A Olanzapine and fluoxetine 10.7 mg/40.8 mg Lamotrigine mg 7 7 Olanzapine and fluoxetine combination, olanzapine and placebo TOHEN2003 USA Paroxetine, imipramine and placebo NEMEROFF2001 USA 36 NR 70 Quetiapine compared with placebo Lorazepam and anticholinergic therapy Lithium, valproate and/or carbamazepine Olanzapine and fluoxetine 7.4 mg/39.3 mg Olanzapine 9.7 mg Placebo N/A Paroxetine 32.6 mg Imipramine mg Placebo N/A 7 10 SUPPES2010 USA Lorazepam, zolpidem Quetiapine XR 300 mg 7 8 4

5 THASE2006 USA Quetiapine compared with paroxetine tartrate, zaleplon, zopiclone, chloral hydrate and anticholinergics Lorazepam and zolpidem tartrate Placebo N/A Quetiapine 300 mg Quetiapine 600 mg Placebo N/A 7 8 MCELROY2010 Multiple (not specified) Lorazepam, zolpidem tartrate and chloral hydrate Quetiapine 300 mg Quetiapine 600 mg Paroxetine 20 mg Placebo N/A 7 8 Quetiapine, lithium and placebo YOUNG2010 Multiple (not specified) Lorazepam, zolpiclone tartrate, zaleplon, zopliclone and chloral hydrate Quetiapine 300 mg Quetiapine 600 mg Lithium mg Placebo N/A 7 8 Valproate compared with placebo DAVIS2005 USA Bedtime sedatives Valproate 1,250 mg Placebo N/A 7 8 5

6 GHAEMI2007 USA None 10 9 Valproate 1,028.8 mg Placebo N/A 7 6 MUZINA2011 USA Ziprasidone compared with placebo Lorazepam and zolpidem Valproate 1,606 mg Placebo N/A 7 6 PAKAR2012 USA PFIZER2009a USA None PFIZER2009b SACHS2011 GBR, FRA,, IND, USA None Treatment as usual Lamotrigine, lithium or valproate; lorazepam NR NR Ziprasidone mg 7 6 NR NR Placebo N/A NR Ziprasidone 40 mg NR Placebo N/A NR Ziprasidone 20 mg NR Ziprasidone 40 mg NR Placebo N/A Ziprasidone 40 mg Placebo N/A

7 1.2 NUTRITIONAL INTERVENTIONS Nutritional interventions Omega-3 fatty acids compared with placebo KECK2006B NR Mood stabilisers 59 NR Eicosapentaenoic acid 6,000 mg NR Placebo N/A PHYSICAL INTERVENTIONS Physical interventions Acupuncture compared with sham acupuncture DENNEHY2009B USA Bright light therapy compared with low-density and high density air ionization Medication as usual 13 NR Acupuncture N/A NR Sham N/A Bright light therapy N/A 7 8 DAUPHINAIS2012 USA NR Medication as usual Low-density negative air ionization N/A Highdensity negative air ionization N/A 7 8 7

8 Chronotherapeutic augmentation treatment compared with treatment as usual (TAU) WU2009 USA NR Lithium and antidepressants Sleep deprivation, bright light therapy and sleep phase advance N/A TAU N/A 1 7 Transcranial magnetic stimulation (TMS) compared with sham TMS NAHAS2003 USA Carbamazepine, valproate or combination TMS Sham TMS 20 minutes 20 minutes